AMBER VERCELLINE: Open Payments
NPI 1841895356 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,686 in 67 payments from 20 companies in 2025. Trend: 2023 $1,132 · 2024 $1,215 · 2025 $1,686
Food & beverage: $1,686
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 12 | $209 |
| AstraZeneca Pharmaceuticals LP | 7 | $203 |
| Insmed, Inc. | 8 | $171 |
| Penumbra, Inc. | 1 | $166 |
| Actelion Pharmaceuticals US, Inc. | 6 | $165 |
| GENZYME CORPORATION | 4 | $111 |
| Lilly USA, LLC | 1 | $110 |
| Viatris Specialty LLC | 4 | $97 |
| Regeneron Healthcare Solutions, Inc. | 2 | $78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $64 |
Products named: DUPIXENT, Arikayce, Indigo System, TRELEGY ELLIPTA, OPSUMIT, AIRSUPRA, TEZSPIRE, YUPELRI.
Industry payments across AZ — which companies pay providers there.
